Table 1.
Patient demographic and disease characteristics for LEGENDScreen™ discovery cohort (UK based).
| Healthy Controls | RA (adalimumab ADA−) | RA (adalimumab ADA+) | DMARDs treated RA (biologic naïve) | |
|---|---|---|---|---|
| n | 18 | 10 | 10 | 10 |
| Sex, female n (%) | 15 (79) | 7 (70) | 9 (90) | 9 (90) |
| Age (years), mean (SD) | 35.2 (10.7) | 62.4 (14.8) | 53.4 (10.5) | 45.6 (13.5) |
| DAS28 (SD) | – | 3.05 (1.06) | 3.63 (1.69) | 3.95 (1.76) |
| Seropositive (RF+/CCP+) (%) | – | 100 | 90 | 100 |
| CRP mg/l (SD) | – | 14.07 (21.54) | 5.64 (6.20) | 6.78 (4.75) |
| CURRENT TREATMENT | ||||
| DMARDs only (n) | – | 3* | 1* | 10 |
| Adalimumab (n) | – | 5 | 8 | – |
| Etanercept (n) | – | 1* | – | – |
| Tocliziumab (n) | – | 1* | 1* | – |
| CONCOMITANT DMARD TREATMENT | ||||
| MTX use, n (%) | – | 7 | 5 | 5 |
| Average MTX dose, mg/week, mean (SD) | – | 15.7 (3.6) | 18 (51.1) | 19 (2.0) |
| Prednisolone use, n (%) | – | 1 | 2 | 2 |
| Hydroxychloroquine use, n (%) | – | 1 | 2 | 6 |
| Sulfasalazine use, n (%) | – | 1 | 1 | 6 |
In the discovery cohort there are no statistical differences between ADA+ and ADA− RA patient groups (t-test, p < 0.05 was considered as significant), nor between ADA+ and ADA− and DMARDs treated (ANOVA), expect for age between ADA− and DMARDs.
At point of sampling patients receiving a non-adalimumab treatment as indicated (Current Treatment) but have previously been treated with adalimumab and tested for ADA against adalimumab.
Values in the table represent mean ± standard deviation (SD), or number of patients (n) with proportion of total (%) where indicated.
Adalimumab dose 40 mg every 2 weeks, tocilizumab dose 4 mg/kg every 4 weeks, etanercept does 25 mg twice a week.